SCHEMBL13289271

SCHEMBL13289271

Bc1cnn2c(NCCCCNS(=O)(=O)c3ccc(Oc4ccccc4)cc3)cc(-c3ccccc3O)nc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MMP2 P08253 7/20 0.44
▸ CA12 O43570 5/20 0.44
▸ CA1 P00915 5/20 0.44
▸ CA2 P00918 5/20 0.44
▸ CA9 Q16790 5/20 0.44
▸ ADAMTS4 O75173 2/20 0.39
▸ MMP13 P45452 2/20 0.39
▸ MMP14 P50281 2/20 0.39
▸ ADAMTS5 Q9UNA0 2/20 0.39
▸ MAPT P10636 5/20 0.37
▸ TP53 P04637 2/20 0.37
▸ GSK3B P49841 4/20 0.36
▸ MMP1 P03956 1/20 0.36
▸ MEP1B Q16820 1/20 0.36
▸ LMNA P02545 3/20 0.34
▸ HTT P42858 2/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ STAT3 P40763 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14546013 0.86 GSK3B (0.47) MMP2CA12CA1CA2CA9
SCHEMBL14051103 0.85 GAA (0.37) MMP2MAPTTP53GSK3BMMP1
SCHEMBL14545891 0.85 CA12 (0.39) MMP2CA12CA1CA2CA9
SCHEMBL14613413 0.84 GSK3B (0.36) MAPTTP53GSK3BSMN1; SMN2ALDH1A1
SCHEMBL13289501 0.83 ALDH1A1 (0.47) GSK3BALDH1A1
SCHEMBL13289270 0.83 CDK2 (0.46) MAPTGSK3BLMNASMN1; SMN2ALDH1A1
SCHEMBL14545272 0.82 GSK3B (0.36) CA12CA2CA9MAPTGSK3B
SCHEMBL14613411 0.82 GSK3B (0.33) MAPTTP53GSK3BSMN1; SMN2
SCHEMBL13289057 0.81 GSK3B (0.46) MAPTTP53GSK3BLMNASMN1; SMN2
SCHEMBL13289243 0.81 GSK3B (0.46) MAPTTP53GSK3BHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2194058-A1 Pyrazolopyrimidines suitable for the treatment of cancer diseases SCHERING CORPORATION (US) 2010-06-09 — — EP disclosed
Send feedback